Treats Hypertension. ANDA 75646, held by Chartwell Rx. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75646 (Doxazosin Mesylate), held by Chartwell Rx, was first approved by FDA on Oct 18, 2000, with 2 approved supplements and 0 published complete response letters.
Doxazosin mesylate tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Discontinued |
| Feb 21, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 21, 2001 | Supplement 1Labeling | Approved | None posted |
| Oct 18, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters